{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:07:23Z","timestamp":1790762843629,"version":"4.1.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007359","name":"Fondazione Banco di Sardegna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00382","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T08:20:59Z","timestamp":1531210859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Marta A.","family":"Kowalik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Columbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Perra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1152\/physrev.2001.81.3.1097","article-title":"Physiological and molecular basis of thyroid hormone action","volume":"81","author":"Yen","year":"2001","journal-title":"Physiol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0889-8529(05)70294-2","article-title":"Mechanisms of thyroid hormone action","volume":"27","author":"Motomura","year":"1998","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"601361","DOI":"10.1155\/2013\/601361","article-title":"Molecular functions of thyroid hormones and their clinical significance in liver-related diseases","volume":"2013","author":"Chi","year":"2013","journal-title":"Biomed Res Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"G852","DOI":"10.1152\/ajpgi.00521.2005","article-title":"Lipid metabolism and liver inflammation","volume":"290","author":"Reddy","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B6","first-page":"1388","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume-title":"J Hepatol.","author":"European","year":"2016"},{"key":"B7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc."},{"key":"B8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)42721-X","article-title":"Choline-deficiency fatty liver: impaired release of hepatic triglycerides","volume":"9","author":"Lombardi","year":"1968","journal-title":"J Lipid Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/j.1440-1746.2006.04701.x","article-title":"Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model","volume":"22","author":"Vetel\u00e4inen","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"FASEB J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI15650","article-title":"What does Stat3 do?","volume":"109","author":"Levy","year":"2002","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.nutr.21.1.193","article-title":"Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system","volume":"21","author":"Reddy","year":"2001","journal-title":"Annu Rev Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41598-017-02205-1","article-title":"Metabolomic analysis shows differential hepatic effects of T(2) and T(3) in rats after short-term feeding with high fat diet","volume":"7","author":"Iannucci","year":"2017","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1172\/JCI60580","article-title":"Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy","volume":"122","author":"Sinha","year":"2012","journal-title":"J Clin Invest."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2169\/internalmedicine.55.6640","article-title":"Hyperthyroidism improves the pathological condition of nonalcoholic steatohepatitis: a case of nonalcoholic steatohepatitis with Graves' disease","volume":"55","author":"Miyake","year":"2016","journal-title":"Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/ncpendmet0190","article-title":"Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance","volume":"2","author":"Roden","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J Clin Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.molmet.2016.01.008","article-title":"Essential role of UCP1 modulating the central effects of thyroid hormones on energy balance","volume":"5","author":"Alvarez-Crespo","year":"2016","journal-title":"Mol Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/hep.27388","article-title":"Emerging trends in hepatocellular carcinoma incidence and mortality","volume":"61","author":"Njei","year":"2015","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP investigators study group","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cgh.2006.07.011","article-title":"Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.22793","article-title":"Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States","volume":"49","author":"Hassan","year":"2009","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"R353","DOI":"10.1530\/ERC-16-0152","article-title":"T3\/TRs axis in hepatocellular carcinoma: new concepts for an old pair","volume":"23","author":"Perra","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B26","first-page":"603","article-title":"Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas","volume":"60","author":"Ledda-Columbano","year":"2000","journal-title":"Cancer Res."},{"key":"B27","first-page":"595","article-title":"Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis","volume":"88","author":"Solt","year":"1977","journal-title":"Am J Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/hep.22750","article-title":"Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype","volume":"49","author":"Perra","year":"2009","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0021-9258(19)45540-3","article-title":"Induction of deoxyribonucleic acid synthesis in the liver of the intact animal","volume":"247","author":"Short","year":"1972","journal-title":"J Biol Chem."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.1840200521","article-title":"Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro","volume":"20","author":"Francavilla","year":"1994","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1096\/fj.00-0416com","article-title":"Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3)","volume":"15","author":"Pibiri","year":"2001","journal-title":"FASEB J."},{"key":"B32","first-page":"186","article-title":"Experimental pathology of the liver","volume":"12","author":"Higgins","year":"1931","journal-title":"Arch Pathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000098443","article-title":"Tri-iodothyronine as a stimulator of liver regeneration after partial and subtotal hepatectomy","volume":"39","author":"Bockhorn","year":"2007","journal-title":"Eur Surg Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2184.2008.00532.x","article-title":"Triiodothyronine stimulates hepatocyte proliferation in two models of impaired liver regeneration","volume":"41","author":"Columbano","year":"2008","journal-title":"Cell Prolif."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/j.1600-6143.2005.00949.x","article-title":"Exogenous thyroid hormone induces liver enlargement, whilst maintaining regenerative potential\u2013a study relevant to donor preconditioning","volume":"5","author":"Malik","year":"2005","journal-title":"Am J Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/0002-9343(90)90530-Q","article-title":"Biochemical basis of thyroid hormone action in the heart","volume":"88","author":"Dillmann","year":"1990","journal-title":"Am J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM200102153440707","article-title":"Thyroid hormone and the cardiovascular system","volume":"344","author":"Klein","year":"2001","journal-title":"N Engl J Med."},{"key":"B38","first-page":"184","article-title":"Thyroid hormone receptors: multiple forms, multiple possibilities","volume":"14","author":"Lazar","year":"1993","journal-title":"Endocr Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJM199409293311306","article-title":"The molecular basis of thyroid hormone action","volume":"331","author":"Brent","year":"1994","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1152\/physrev.2001.81.3.1269","article-title":"Nuclear hormone receptors and gene expression","volume":"81","author":"Aranda","year":"2001","journal-title":"Physiol Rev."},{"key":"B42","first-page":"912","article-title":"The resurgence of thyromimetics as lipid-modifying agents","volume":"10","author":"Tancevski","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1089\/thy.2012.0458","article-title":"Thyroid hormone analogues: where do we stand in 2013?","volume":"23","author":"Meruvu","year":"2013","journal-title":"Thyroid"},{"key":"B44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/13543784.13.5.489","article-title":"Selective activators of thyroid hormone receptors","volume":"13","author":"Webb","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1210\/endo.141.9.7681","article-title":"The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity","volume":"141","author":"Trost","year":"2000","journal-title":"Endocrinology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.2337\/diabetes.51.4.1166","article-title":"Overrexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy","volume":"51","author":"Trost","year":"2002","journal-title":"Diabetes"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0122987","DOI":"10.1371\/journal.pone.0122987","article-title":"The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob\/ob mice","volume":"10","author":"Martag\u00f3n","year":"2015","journal-title":"PLoS ONE"},{"key":"B50","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1152\/ajpendo.00573.2012","article-title":"Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner","year":"2013","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hep.27399","article-title":"Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats","volume":"61","author":"Frau","year":"2015","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ajpath.2017.07.005","article-title":"Thyroid hormone receptor-\u03b2 agonist GC-1 inhibits Met-\u03b2-catenin-driven hepatocellular cancer","volume":"187","author":"Puliga","year":"2017","journal-title":"Am J Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/hep.28601","article-title":"Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant \u03b2-catenin","volume":"64","author":"Tao","year":"2016","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1210\/en.2005-1561","article-title":"The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas","volume":"147","author":"Columbano","year":"2006","journal-title":"Endocrinology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jhep.2010.04.028","article-title":"TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells","volume":"53","author":"Kowalik","year":"2010","journal-title":"J Hepatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3727\/105221616X691631","article-title":"Thyroid hormone receptor \u03b2 agonist induces \u03b2-catenin-dependent hepatocyte proliferation in mice: implications in hepatic regeneration","volume":"17","author":"Alvarado","year":"2016","journal-title":"Gene Expr."},{"key":"B57","doi-asserted-by":"publisher","first-page":"15358","DOI":"10.1073\/pnas.2136689100","article-title":"Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor","volume":"100","author":"Borngraeber","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1677\/JOE-08-0539","article-title":"A TRbeta-selective agonist confers resistance to diet-induced obesity","volume":"203","author":"Amorim","year":"2009","journal-title":"J Endocrinol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1021\/jm021080f","article-title":"Thyroid receptor ligands","volume":"46","author":"Ye","year":"2003","journal-title":"J Med Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1527-3466.2005.tb00161.x","article-title":"Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects","volume":"23","author":"Grover","year":"2005","journal-title":"Cardiovasc Drug Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B63","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3727\/105221617X695438","article-title":"The Thyromimetic KB2115 (Eprotirome) Induces Rat Hepatocyte Proliferation","volume":"17","author":"Szydlowska","year":"2017","journal-title":"Gene Expr."},{"key":"B65","doi-asserted-by":"publisher","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","article-title":"Sobetirome ss a thyroid hormone receptor\u03b2- and liver-selective thyromimetic that can effect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men","author":"Lin","year":"2008","journal-title":"90th Annual Meeting of the Endocrine Society"},{"key":"B67","year":"2006","journal-title":"88th Annual Meeting of the Endocrine Society Program and Abstracts"},{"key":"B68","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1016\/j.bbagen.2012.08.019","article-title":"Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling","volume":"1830","author":"Arrojo","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ygcen.2014.02.014","article-title":"3,5-Diiodothyronine (T2) is on a role. A new hormone in search of recognition","volume":"203","author":"Orozco","year":"2014","journal-title":"Gen Comp Endocrinol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1530\/JME-15-0156","article-title":"New insights into the structure and mechanism of iodothyronine deiodinases","volume":"55","author":"Schweizer","year":"2015","journal-title":"J Mol Endocrinol."},{"key":"B74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1677\/jme.0.0190137","article-title":"3,5-Diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro","volume":"19","author":"Ball","year":"1997","journal-title":"J Mol Endocrinol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1469-7793.1997.529bb.x","article-title":"How the thyroid controls metabolism in the rat: different roles for triiodothyronine and diiodothyronines","volume":"505","author":"Moreno","year":"1997","journal-title":"J Physiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-13-0573","article-title":"Thyroid: biological actions of 'nonclassical' thyroid hormones","volume":"221","author":"Senese","year":"2014","journal-title":"J Endocrinol."},{"key":"B77","first-page":"505","article-title":"PAT protein mRNA expression in primary rat hepatocytes: Effects of exposure to fatty acids","volume":"25","author":"Grasselli","year":"2010","journal-title":"Int J Mol Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jhep.2010.09.027","article-title":"Direct effects of iodothyronines on excess fat storage in rat hepatocytes","volume":"54","author":"Grasselli","year":"2011","journal-title":"J Hepatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/j.1440-1746.2008.05543.x","article-title":"Animal models of NASH: getting both pathology and metabolic context right","volume":"23","author":"Larter","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1096\/fj.05-3977fje","article-title":"3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats","volume":"19","author":"Lanni","year":"2005","journal-title":"FASEB J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jhep.2009.03.023","article-title":"3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet","volume":"51","author":"Mollica","year":"2009","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1039\/c0mb00040j","article-title":"Pathways affected by 3,5-diiodo-l-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry","volume":"6","author":"Silvestri","year":"2010","journal-title":"Mol Biosyst"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.2337\/db11-0207","article-title":"Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats","volume":"60","author":"de","year":"2011","journal-title":"Diabetes"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20070140","article-title":"Sirtuins in mammals: insights into their biological function","volume":"404","author":"Michan","year":"2007","journal-title":"Biochem J"},{"key":"B85","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1074\/jbc.M112.437970","article-title":"Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone","volume":"288","author":"Thakran","year":"2013","journal-title":"J Biol Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e70097","DOI":"10.1371\/journal.pone.0070097","article-title":"SIRT1 is a direct coactivator of thyroid hormone receptor \u03b21 with gene-specific actions","volume":"8","author":"Suh","year":"2013","journal-title":"PLoS ONE"},{"key":"B87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1074\/jbc.M115.668673","article-title":"Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition","volume":"291","author":"Singh","year":"2016","journal-title":"J Biol Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev.nu.10.070190.002005","article-title":"Lipoprotein assembly and secretion by hepatocytes","volume":"10","author":"Vance","year":"1990","journal-title":"Annu Rev Nutr."},{"key":"B89","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1530\/JOE-11-0288","article-title":"3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver","volume":"212","author":"Grasselli","year":"2012","journal-title":"J Endocrinol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cmet.2011.12.018","article-title":"Fat signals\u2013lipases and lipolysis in lipid metabolism and signaling","volume":"15","author":"Zechner","year":"2012","journal-title":"Cell Metab."},{"key":"B91","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphys.2017.00706","article-title":"Both 3,5-Diiodo-L-Thyronine and 3,5,3'-Triiodo-L-Thyronine Prevent Short-term Hepatic Lipid Accumulation via Distinct Mechanisms in Rats Being Fed a High-Fat Diet","volume":"14","author":"Senese","year":"2017","journal-title":"Front Physiol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/en.2014-1604","article-title":"3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice","volume":"156","author":"Jonas","year":"2015","journal-title":"Endocrinology"},{"key":"B94","first-page":"655","article-title":"3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects","volume":"25","author":"Antonelli","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1096\/fj.10-157115","article-title":"TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet","volume":"24","author":"Cioffi","year":"2010","journal-title":"FASEB J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4:5","DOI":"10.2147\/DMSOTT.S15323","article-title":"TRC150094 attenuates progression of non-traditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats","volume":"6","author":"Zambad","year":"2011","journal-title":"Diabetes Metab Syndr Obes."},{"key":"B97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1172\/JCI108456","article-title":"An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man","volume":"58","author":"Chopra","year":"1976","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/apha.12821","article-title":"3,5-diiodothyronine (3,5-T2) reduces blood glucose independently of insulin sensitization in obese mice","volume":"220","author":"da","year":"2017","journal-title":"Acta Physiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1210\/en.2010-0491","article-title":"Tissue distribution and cardiac metabolism of 3-iodothyronamine","volume":"151","author":"Saba","year":"2010","journal-title":"Endocrinology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1096\/fj.06-7474com","article-title":"Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function","volume":"21","author":"Chiellini","year":"2007","journal-title":"FASEB J"},{"key":"B101","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/sj.bjp.0706948","article-title":"Trace amine-associated receptors and their ligands","volume":"149","author":"Zucchi","year":"2006","journal-title":"Br J Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm1051","article-title":"3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone","volume":"10","author":"Scanlan","year":"2004","journal-title":"Nat Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1039\/b926583j","article-title":"3-Iodothyronamine (T(1)AM): a new chapter of thyroid hormone endocrinology?","volume":"6","author":"Ianculescu","year":"2010","journal-title":"Mol Biosyst."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0040","article-title":"Thyronamines\u2013past, present, and future","volume":"32","author":"Piehl","year":"2011","journal-title":"Endocr Rev."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1115","article-title":"Detection of 3-iodothyronamine in human patients: a preliminary study","volume":"97","author":"Galli","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1210\/jc.2010-2680","article-title":"Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay","volume":"96","author":"Hoefig","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B107","doi-asserted-by":"publisher","first-page":"CD0116","DOI":"10.1002\/14651858.CD011640.pub2","article-title":"Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis","volume":"3","author":"Lombardi","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1677\/JOE-09-0043","article-title":"Central effects of thyronamines on glucosemetabolism in rats","volume":"201","author":"Klieverik","year":"2009","journal-title":"J Endocrinol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/JOE-13-0311","article-title":"Uptake and metabolic effects of 3-iodothyronamine in hepatocytes","volume":"221","author":"Ghelardoni","year":"2014","journal-title":"J Endocrinol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.M111.235044","article-title":"Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line","volume":"286","author":"Vil\u00e0-Brau","year":"2011","journal-title":"J Biol Chem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e106923","DOI":"10.1371\/journal.pone.0106923","article-title":"Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern","volume":"9","author":"Mariotti","year":"2014","journal-title":"PLoS ONE"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1002\/oby.20391","article-title":"NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment","volume":"21","author":"Haviland","year":"2013","journal-title":"Obesity"},{"key":"B113","doi-asserted-by":"publisher","first-page":"16475","DOI":"10.1038\/s41598-017-16593-x","article-title":"Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer","volume":"7","author":"Shinderman-Maman","year":"2017","journal-title":"Sci Rep."},{"key":"B114","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/2211-5463.12205","article-title":"Uptake of 3-iodothyronamine hormone analogs inhibits the growth and viability of cancer cells","volume":"7","author":"Rogowski","year":"2017","journal-title":"FEBS Open Bio."},{"key":"B115","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1476-5381.2011.01823.x","article-title":"3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice","volume":"166","author":"Manni","year":"2012","journal-title":"Br J Pharmacol."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T13:46:51Z","timestamp":1751723211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":115,"alternative-id":["10.3389\/fendo.2018.00382"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00382","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"article-number":"382"}}